Arch Biopartners Inc., a clinical stage company targeting acute organ inflammation with novel therapeutics, has added Dr. David Luke as a Strategic Advisor for the clinical trial development of the company’s drug candidates.   Dr. Luke previously held a variety of positions in the pharma industry, including approximately twenty years at Pfizer Inc, where he was a Senior Medical Director, responsible for planning and executing human trials in the areas of infectious diseases, oncology, immunolo...